Stay updated with breaking news from Connection Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Investegate announcements from Infant Bacterial Therapeutics, Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – December 31, 2021
Investegate announcements from Infant Bacterial Therapeutics, The Connection Study continues after pre-scheduled Data Monitoring Committee (DMC) review
Investegate announcements from Infant Bacterial Therapeutics, A Blinded Evaluation of the Connection Study – Sustained Feeding Tolerance (SFT) Correlates to Clinical Outcomes
A blinded evaluation of IBT's Connection Study will be presented by Professor Josef Neu, University of Florida, at the 2021 Hot Topics in Neonatology on December 6, 2021. The evaluation reveals that even
Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 - March 31, 2021 Message from the CEO IBT is conducting a phase III-study ("The Connection Study") which is the last phase of the clinical development program with the pharmaceutical candidate IBP-9414 containing Lactobacillus reuteri as active substance. The active substance is a human bacterial strain found naturally in breast milk. The objective of the study is to show that the active substance can prevent necrotizing enterocolitis (NEC) and improve sustained feeding tolerance. The medical need of a well-func...